10-K: 10x Genomics Reports Mixed 2024 Results Amidst Strategic Shifts and Legal Battles

10x Genomics' 2024 revenue slightly decreased by 1% year-over-year, accompanied by a reduced net loss, as the company navigated strategic changes and ongoing intellectual property litigation.

Summary

• 10x Genomics' 2024 revenue was $610.8 million, a 1% decrease from $618.7 million in 2023.
• The company reported a net loss of $182.6 million for 2024, an improvement from the $255.1 million loss in 2023.
• Instrument sales decreased by 25%, while consumables revenue increased by 3%.
• The company sold 1,073 instruments and 357,100 consumable reactions in 2024, compared to 1,336 instruments and 347,000 consumable reactions in 2023.
• The company is involved in ongoing intellectual property litigation, including disputes with NanoString and Vizgen.
• The company is implementing strategic price reductions and discounting of products and services.
• The company is dependent on government funding and research and development spending by research institutions.
• The company is expanding its international operations, particularly in the Asia-Pacific region.
• The company is dependent on single source and sole source suppliers for some of the equipment, components and materials used in its products.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the net loss has decreased, revenue has also declined. The company faces significant competition and ongoing litigation, but also has a strong intellectual property portfolio and a talented team.

Positives

• Net loss decreased from $255.1 million in 2023 to $182.6 million in 2024.
• Consumables revenue increased by 3% in 2024.
• Service revenue increased by 57% in 2024.
• The company has a strong intellectual property portfolio with over 1,290 issued or allowed patents and 1,300 pending patent applications.
• The company is ISO 9001:2015 certified for its manufacturing operations.
• The company has a talented, global and diverse team of scientists, software developers and subject matter experts.
• The company has a strong research and development pipeline.
• The company has a strong customer base of academic, government, biopharmaceutical, biotechnology and other institutions.
• The company has a strong commercial organization with 491 full time employees.
• The company has a strong online community of users of its products.

Negatives

• Overall revenue decreased by 1% in 2024.
• Instrument sales decreased by 25% in 2024.
• The company has incurred significant losses since inception and expects to incur losses in the future.
• The company is involved in ongoing intellectual property litigation, which is expensive and time-consuming.
• The company is dependent on government funding and research and development spending by research institutions.
• The company is dependent on single source and sole source suppliers for some of the equipment, components and materials used in its products.
• The company is subject to risks related to taxation in multiple jurisdictions and changes in tax laws or regulations.
• The company is subject to ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing.

Risks

• Fluctuations in operating results due to various factors, including government funding, competition, and trade barriers.
• Dependence on government funding and research and development spending by research institutions.
• Intense competition in the life sciences industry.
• Potential negative impact from price reductions and discounting.
• Harm to business from enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers.
• Inability to increase penetration in existing customer segments.
• Smaller than estimated market size for solutions.
• Complexity of data generated by products.
• Inability to consistently manufacture instruments and consumables to necessary specifications.
• Dependence on revenue generated from the sale of Chromium solutions.
• Operational and financial risks associated with doing business internationally.
• Dependence on single source and sole source suppliers for some of the equipment, components and materials used in its products.
• Limited operating history and fluctuations in revenue.
• Failure of existing and new products to achieve and sustain sufficient scientific acceptance.
• Inability to sustain or successfully manage growth.
• Inability to generate sufficient revenue to achieve and maintain cash flows from operating activities in excess of capital investment requirements or profitability.
• Products could become subject to more onerous government regulation.
• Changes in tax laws or regulations that are applied adversely to us or our customers.
• Ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing.
• Inability to obtain, maintain and protect intellectual property rights.
• Dependence on certain intellectual property rights that are licensed to us.
• Potential involvement in lawsuits in connection with intellectual property rights.
• Inability to effectively protect and enforce intellectual property rights.
• The multi-class structure of our common stock.
• The requirement of our bylaws that the State of Delaware is the exclusive forum for substantially all disputes between us and our shareholders.
• Inability to meet publicly announced guidance or other expectations about our business.
• Volatility of the market price of our Class A common stock.

Future Outlook

The company expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term. The company expects its expenses will modestly increase in connection with its ongoing activities, including in connection with its efforts to attract, hire and retain qualified personnel. Excluding acquisitions, the company does not expect its operating expenditures to meaningfully increase in 2025.

Industry Context

The life sciences industry is highly competitive, with companies introducing products for genomics analysis, single cell analysis, spatial analysis and in situ analysis. 10x Genomics competes with established and early-stage companies, as well as companies offering existing tools and technologies for life science research.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• The document mentions Illumina, Inc., the largest sequencer manufacturer, and its designation by Chinas Ministry of Commerce (MOFCOM) as an unreliable entity, which could impact 10x Genomics' business in China.

Legal Proceedings

• The company is involved in ongoing intellectual property litigation, including disputes with NanoString and Vizgen.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the ongoing litigation.
• Employees may be affected by the restructuring plan and potential changes in strategy.
• Customers may benefit from the company's continued investment in research and development and the introduction of new products.
• Suppliers may be affected by the company's efforts to manage supply chain risks.

Next Steps

• Continue to invest in research and development to enhance existing products and develop new products.
• Expand sales efforts globally.
• Adjust prices for instruments and consumables to drive increased adoption.
• Continue to monitor and manage intellectual property litigation.
• Continue to monitor and manage supply chain risks.
• Continue to monitor and manage risks related to taxation in multiple jurisdictions.
• Continue to monitor and manage ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing.

Key Dates

Keywords

Genomics, Single Cell Analysis, Spatial Analysis, In Situ Analysis, Instruments, Consumables, Research Tools, Life Sciences, Financial Results, 10x Genomics